Table 2. Clinical outcomes of patients infected with Klebsiella pneum

Clinical outcome	non-CRKP	CRKP	CoRKP	P-value		
	(n=58)	(n=10)	(n=28)	non-CRKP vs CRKP	non-CRKP vs CoRKP	CRKP vs CoRKP
14-day mortality	7 (12.07)	4 (40)	17 (60.71)	0.049	< 0.05	0.293
In hospital mortality	12 (20.69)	7 (70)	23 (82.14)	0.007	< 0.05	0.411
Microbiological failure	2/33 (6.06)	2/6 (33.33)	9/17 (52.94)	0.104	< 0.05	0.64




Figure 1. The 14-day and in hospital mortality of patients infected with K. pneumoniae bacteremia (n=96)

Table 3. The 14-day survival rate of patients infected colistin-resistant K. pneumoniae bactere (n=28)

Treatment regimen	14-day survival rate	P-value	
colistin-including therapy	1/11 (9.09)	< 0.05	
colistin-excluding therapy	10/17 (58.82)		
Fluoroquinolone-based	1/1 (100.00)		
cephalosporin-based	-		
β -lactam/ β -lactamse inhibitor-based	-		
carbapenem-based	-		
aminoglycoside-based	9/16 (56.25)		
AG + FOF	3/8 (37.50)		
AG + TGC	1/3 (33.33)		
AG + FOF + TGC	3/3 (100.00)		
AG + other *	2/2 (100.00)		

Disclosures. All authors: No reported disclosures.

2285. Emergence of perioperative antibiotic non-susceptible pathogens causing prosthetic joint infections in monomicrobial Gram-negative and polymicrobial infections

Meredith M. Coyle, MD¹; Kathleen M. Riederer, MT (ASCP)²; Babak Hooshmand, MD³; Dima Youssef, MD²; Ashish Bhargava, MD⁴; ¹St. John's Ascension, Detroit, Michigan; ²Ascension St. John Hospital, Grosse Pointe, Michigan; ³Ascension Health, Saint John Hospital and Medical Center, Grosse Pointe Woods, Michigan; ⁴Ascension St John, Grosse Pointe Woods, Michigan

Session: 246. Clincal Outcomes of Infections with Resistant Organisms Saturday, October 5, 2019: 12:15 PM


Current recommendations by Infectious diseases society of Background. America (IDSA) endorse cefazolin for perioperative use. What is less known currently is the emergence of resistance in Gram-positive (GP) and Gram-negative (GN) prosthetic joint infections (PJIs) in the setting of perioperative use of antibiotics.

Methods. A retrospective multi-centric cohort was studied at three hospitals from January 2012 to December 2018. Patients with PJIs were identified using ICD codes. We reviewed electronic medical records and identified PJIs which followed primary arthroplasties. We included cases where perioperative antibiotics records were available.

Results. 66 infected PJIs with available preoperative records were included. 40 (61%) patients were females, and 42 (64%) were caucasians. Indications for undergoing arthroplasty were degenerative joint disease (DJD) in 52 (78%), trauma in 13 (20%) and avascular necrosis in 1 (1.5%). Sites for arthroplasty were knee in 33 (50%), hip 28 (42.5%), shoulder 4 (6%), and ankle in 1(1.5%). 43 (65%) had GP monomicrobial, 6 (9%) had GN monomicrobial and 17 (26%) had polymicrobial infections. 40 (60.5%) patients received cefazolin, 25 (38%) received vancomycin and 1 (1.5%) received ceftriaxone as perioperative prophylaxis. 7 (11%) PJIs among monomicrobial infections and 6 (35%) among polymicrobial infections had non-susceptible (NS) organisms (Figure 1 and 2). 8 (47%) polymicrobial PJIs had a mixed susceptibility profile with drug susceptible and resistant organisms.

In general, when monomicrobial GP pathogens are causative for Conclusion. PJI, current use of cefazolin as perioperative drug of choice is sound and we agree with the current perioperative recommendations. It should be recognized that in situations where the PJI is due to GN or is polymicrobial, resistance to perioperative antibiotics may be present at a greater rate. From this study we conclude that in cases where the pathogen is known to be GN or polymicrobial from a diagnostic aspiration, then a broader antibiotic selection may be of benefit perioperatively.

Figure 1. Monomicrobial Infections with perioperative antibiotic regimen indicated.







Figure 2. Polymicrobial infections with perioperative antibiotic regimen indicated.



Disclosures. All authors: No reported disclosures.

2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia Matthew Mills, PharmD¹; Ashley MacWhinnie, PharmD, BCPS¹; Timmy Do, PharmD, BCPS¹; ¹AdventHealth East Orlando, Orlando, Florida